» Articles » PMID: 22262068

Physiology of Incretins in Health and Disease

Overview
Journal Rev Diabet Stud
Specialty Endocrinology
Date 2012 Jan 21
PMID 22262068
Citations 43
Authors
Affiliations
Soon will be listed here.
Abstract

The incretin hormones, glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), are gut peptides which are secreted by endocrine cells in the intestinal mucosa. Their plasma concentrations increase quickly following food ingestion, and carbohydrate, fat, and protein have all been shown to stimulate GLP-1 and GIP secretion. Although neural and hormonal mechanisms have also been proposed to regulate incretin hormone secretion, direct stimulation of the enteroendocrine cells by the presence of nutrients in the intestinal lumen is probably the most important factor in humans. The actions of the incretin hormones are crucial for maintaining normal islet function and glucose homeostasis. Furthermore, it is also now being recognized that incretin hormones may have other actions in addition to their glucoregulatory effects. Studies have shown that GLP-1 and GIP levels and actions may be perturbed in disease states, but interpretation of the precise relationship between disease and incretins is difficult. The balance of evidence seems to suggest that alterations in secretion and/or action of incretin hormones arise secondarily to the development of insulin resistance, glucose intolerance, and/or increases in body weight rather than being causative factors. However, these impairments may contribute to the deterioration of glycemic control in diabetic patients.

Citing Articles

The role of amylin, a gut-brain axis hormone, in metabolic and neurological disorders.

Muhammad T, Pastore S, Good K, Yu W, Vincent J FASEB Bioadv. 2025; 7(3):e1480.

PMID: 40060942 PMC: 11886606. DOI: 10.1096/fba.2024-00151.


Polyphenols in foods: a potential strategy for preventing and managing the postprandial hyperglycemic response.

Kim K, Kim J Food Sci Biotechnol. 2024; 33(12):2699-2713.

PMID: 39184987 PMC: 11339232. DOI: 10.1007/s10068-024-01607-y.


Glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors, anti-diabetic drugs in heart failure and cognitive impairment: potential mechanisms of the protective effects.

Riemma M, Mele E, Donniacuo M, Telesca M, Bellocchio G, Castaldo G Front Pharmacol. 2024; 15:1422740.

PMID: 38948473 PMC: 11212466. DOI: 10.3389/fphar.2024.1422740.


Sensory Nutrition and Bitterness and Astringency of Polyphenols.

Osakabe N, Shimizu T, Fujii Y, Fushimi T, Calabrese V Biomolecules. 2024; 14(2).

PMID: 38397471 PMC: 10887135. DOI: 10.3390/biom14020234.


Psychiatric adverse events associated with semaglutide, liraglutide and tirzepatide: a pharmacovigilance analysis of individual case safety reports submitted to the EudraVigilance database.

Tobaiqy M, Elkout H Int J Clin Pharm. 2024; 46(2):488-495.

PMID: 38265519 PMC: 10960895. DOI: 10.1007/s11096-023-01694-7.


References
1.
Vardarli I, Nauck M, Kothe L, Deacon C, Holst J, Schweizer A . Inhibition of DPP-4 with vildagliptin improved insulin secretion in response to oral as well as "isoglycemic" intravenous glucose without numerically changing the incretin effect in patients with type 2 diabetes. J Clin Endocrinol Metab. 2011; 96(4):945-54. DOI: 10.1210/jc.2010-2178. View

2.
Salehi M, Vahl T, DAlessio D . Regulation of islet hormone release and gastric emptying by endogenous glucagon-like peptide 1 after glucose ingestion. J Clin Endocrinol Metab. 2008; 93(12):4909-16. PMC: 2626449. DOI: 10.1210/jc.2008-0605. View

3.
Deacon C, Johnsen A, Holst J . Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J Clin Endocrinol Metab. 1995; 80(3):952-7. DOI: 10.1210/jcem.80.3.7883856. View

4.
Lindgren O, Carr R, Deacon C, Holst J, Pacini G, Mari A . Incretin hormone and insulin responses to oral versus intravenous lipid administration in humans. J Clin Endocrinol Metab. 2011; 96(8):2519-24. DOI: 10.1210/jc.2011-0266. View

5.
Edwards C, Todd J, Mahmoudi M, Wang Z, Wang R, Ghatei M . Glucagon-like peptide 1 has a physiological role in the control of postprandial glucose in humans: studies with the antagonist exendin 9-39. Diabetes. 1999; 48(1):86-93. DOI: 10.2337/diabetes.48.1.86. View